Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
Pulmonary arterial hypertension is a rare condition that is clinically heterogenous and often diagnosed late in disease progression. Plasma proteomics offers the potential to diagnose earlier, risk-stratify patients, and identify new drug targets.
Learning Objectives
- Pulmonary arterial hypertension as a clinical condition
- Applying proteomics to risk stratification
- Combining proteomics with genome-wide association studies to identify protein quantitative trait loci associated with the condition
Christopher Rhodes, MA, Cantab, PhD
Senior British Heart Foundation Science Fellow
Senior Lecturer
Imperial College London
Martin R. Wilkins
Professor of Clinical Pharmacology
Vice Dean of Research
Faculty of Medicine
Imperial College London
Early detection, risk stratification, and drug target identification in pulmonary arterial hypertension with plasma proteomics
A presentation by Christopher Rhodes, MA, Cantab, PhD, and Martin R. Wilkins
More webinars
WebinarLinking the plasma proteome to echocardiographic parameters in patients with chronic heart failure
Recent advancements in proteomic profiling have unlocked new possibilities for understanding the complex mechanisms that drive heart failure. Measuring thousands of proteins simultaneously makes it possible to capture a comprehensive overview of the patient's health state and investigate underlying disease progression at a subclinical level.
WebinarB Cell Repertoire in Determining Responses to Checkpoint Blockade in NSCLC
In this webinar, Gary Middleton, MD, PhD, and Akshay Patel, PhD, from the University of Birmingham explore the role of the B cell repertoire and autoantibodies in shaping responses to checkpoint blockade immunotherapy in non-small-cell lung cancer (NSCLC). They demonstrate how autoantibody profiling using the i-Ome™ Discovery protein microarray revealed biomarkers predictive of treatment efficacy and immune-related adverse events (irAEs), providing insights into biomarker development and personalized immunotherapy strategies.
WebinarSerum Autoantibodies Differentiate Rheumatoid Arthritis Subgroups
Patients with rheumatoid arthritis (RA) can be categorized as either anti-citrullinated protein antibody-positive (ACPA+) or negative (ACPA-). In this webinar, Dr. Sung will present his research exploring a broad range of serological autoantibodies to uncover immunological differences between these RA subgroups using data from ACPA+ RA patients, ACPA- RA patients, and matched healthy controls.